2 March 2017: Monofer & Diafer (iron isomaltoside) Promotional and Patient Materials
Published 28 April 2017
© Crown copyright 2017
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-march-2017/2-march-2017-monofer-diafer-iron-isomaltoside-promotional-and-patient-materials
Vifor Pharma UK Ltd. complained about a series of promotional and patient materials for Monofer (iron isomaltoside) issued by Pharmacosmos UK Ltd. They considered that ‘One visit’ promotional materials and a patient leaflet exaggerated the benefits of the product and minimised the potential adverse effects.
MHRA did not uphold the complaint. The dose required for iron correction could be administered in one visit and other claims were consistent with the SPC for Monofer.